Tang, X., Chen, L., Li, A., Cai, S., Zhang, Y., Liu, X., . . . Ma, D. (2018). Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv.
シカゴスタイル引用形Tang, Xiaolong, et al. "Anti-GPC3 Antibody-modified Sorafenib-loaded Nanoparticles Significantly Inhibited HepG2 Hepatocellular Carcinoma." Drug Deliv 2018.
MLA引用形式Tang, Xiaolong, et al. "Anti-GPC3 Antibody-modified Sorafenib-loaded Nanoparticles Significantly Inhibited HepG2 Hepatocellular Carcinoma." Drug Deliv 2018.
警告: この引用は必ずしも正確ではありません.